152 results about "Silent gene" patented technology

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.

RNAi vectors comprising a fragment of the SbCSE polynucleotide sequence and transgenic plants, e.g. transgenic sorghum plants, comprising said RNAi vectors are described. Aspects of the technology are further directed to methods of using the RNAi vectors of the present technology to silence SbCSE gene expression or activity in a transgenic plant, such as a transgenic sorghum plant. Silencing the SbCSE gene leads to reduced lignin content in a transgenic plant.

The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ERBB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ERBB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an ERBB gene in a cell or in a subject to treat an ERBB-related disease.

The present invention discloses a method for inducing mesenchymal stem cell to divide into nerve cell and the special culture medium. The culture medium is DMEM culture medium of cattle fetus blood serum which the volume and the thickness percent ratio is 8 to 12 percent. The method is provided with steps as follows: firstly, a small disturbing RNA which restrains the express of limited silent gene of a nerve cell is composed or an intervention carrier of carrying a small disturbing RNA coding gene with restraining the express of limited silent gene of a nerve cell is composed; secondly, the small disturbing RNA which restrains the express of limited silent gene of a nerve cell or the intervention carrier of carrying a small disturbing RNA coding gene with restraining the express of limited silent gene of a nerve cell is transformed or transfected into mesenchymal stem cell or fat stem cell, then the recombined mesenchymal stem cell or the recombined fat stem cell is positioned in the culture medium induced by nerve cell, and cultivated under the temperature of 36 to 38 DEG C, thereby getting nerve cell. The prevent invention can play an important role in the medical field, and has wide applied prospect.

The invention relates to an ABC transportprotein gene ABCH1 and an application of the specific dsRNA of ABCH1 in the prevention and control of diamond back moth and Bt resistance treatment. The invention discloses an insect ABC transportprotein gene and an application of an encoding gene ABCH1 and the double-stranded RNA (dsRNA) of the insect ABC transportprotein gene, and the insect ABC transportprotein gene can specifically silence ABCH1 gene so that Bt Cry1Ac insecticidal protein-sensitive and resistant diamond back moth dies. The gene full-length nucleotide sequence is shown in SEQ ID NO. 1 and is used for encoding the protein as shown in the SEQ ID NO. 2. The invention also discloses ABCH1 gene specific fragments which are used for synthesis of dsRNA; after dsRNA is injected into the Bt Cry1Ac insecticidal protein-sensitive and resistant early 3-year-old diamond back moth larvae body cavity, the diamond back moth slowly develops during the growing process, which results in the death of the diamond back moth in larva and pupa stages. The invention provides a novel target for the prevention and control of field pests and Bt resistance treatment based on RNA interference and thus has good application prospects.

The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.

The invention relates to a gene drug co-carrier system using cation liposome to establish a gold nano-spherical shell and a preparation method. The method comprises: using phosphatides such as DPPC, MPPC and DPPE-PEG and the derivatives thereof to form the cation liposome via membrane extrusion; carrying the hydrophilic drug hydrochloric acid adriacin into the liposome in the forming process; forming the drug-carried cation liposome; adding chlorauric acid solution into cation liposome solution; adsorbing on the surface of the cation liposome; adding ascorbic acid solution for reduction; forming the gold nano-spherical shell structure; reducing sulfhydryl out of the single chain of green fluorescent protein silent gene with a disulfide bond, grafting onto the surface of the gold nano-spherical shell; and forming the gene drug co-carrier system. The gold nano-spherical shell has low toxicity and unique optical properties. The gene drug co-carrier system using cation liposome to establish the gold nano-spherical shell can provide carrier for the co-treatment of drugs and genes, can select light to illuminate the gold nano-spherical shell, and utilize light-heat conversion property to realize the co-release of the drugs and genes.

The invention discloses a method for silencing an IFNARI gene in a DF-1 cell line. The method includes the steps that according to the IFNARI gene, multiple pieces of siRNA of an RNA interference target spot sequence are designed, and the siRNA knocking down IFNARI gene expression at the mRNA level is screened out; a lentiviral vector containing an IFNARI RNAi gene is built; by means of the lentiviral vector, the IFNARI RNAi gene is mediated into the DF-1 cell line to silence IFNARI gene expression, and the proliferation titer of an avian influenza virus in the DF-1 cell line is improved. The method can increase the antigen amount of the avian influenza virus in the DF-1 cell line by 5-10 times, the production cost of a vaccine is greatly reduced, the problems that the vaccine is insufficient in antigen amount and high in production cost can be solved, and the research and development process of an avian influenza bioreactor cell culture technology is promoted.

the invention discloses a little interference RNA to inhibit PRMT5 gene, which is characterized by the following: inhibiting PRMT5 from breeding; treating leukemia and tumour drug target through silent PRMT5 gene.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.

This invention pertains to the development of a screening system to identify (screen for) HER2 promoter silencing agents. Such agents are expected to be of therapeutic value in the treatment of cancers characterized by HER2 amplification/upregulation. In addition, this invention pertains to the discovery that histone deacetylase (HDAC) inhibitors like sodium butyrate and trichostatin A (TSA), in a time and dose dependent fashion can silence gnomical.ly integrated and/or amplified/overexpressing promoters, such as that driving the HER2/ErbB2/neu oncogene, resulting in inhibition of gene products including transcripts and protein, and subsequent production of tumor/cell growth inhibition, apoptosis and/or differentiation. In another embodiment, this invention provides novel SNPs associated with the coding region of the ErbB2. proto-oncogene. The SNPs are indicators for altered risk, for developing ErbB2-positive cancer in a mammal

The invention provides a preparation method of a colon cancer cell strain expressed by stabilized silent PKM2 gene. The preparation method comprises the steps of constructing of shRNA lentiviral expression vector of human PKM2 gene, packaging and obtaining of lentivirus, DLD1 colon cancer lentivirus infecting, stabilized cell strain puromycin screening and Real-time PCR, Western blot identification. The experimental results show that the shRNA nucleotide sequence can be successfully inserted into the pLKO.1-puro expression vector, and the inhibitory effect on the expression of PKM2 gene is remarkable, endurable and stable. The prepared cell strain can be used as the experimental material for researching the regulating effect of PKM2 in malignant characteristics such as colon cancer cell energy metabolism, cell proliferation, cell migration and inflammation.

The invention relates to molecular biology and agricultural biotechnology, and aims to provide a bemisia tabaci defensin gene segment and dsRNA thereof based on the gene silencing technology. The nucleotide sequence of the bemisia tabaci defensin encoding gene segment is as shown in the SEQ ID NO.1. An improved artificial feeding method is adopted to carry out RNAi interference experiment, and compared with an injection method, the improved artificial feeding method has the advantages that mechanical injury of insect bodies can be reduced, operation is convenient, a true sense of natural feeding is realized, and the method can be widely popularized. The dsRNA of the synthesized defensin gene can be used for effectively silencing the defensin gene, has a stable double-stranded structure, is capable of preventing degradation of RNA enzyme, and can be used for laying a foundation for establishing bemisia tabaci gene function researches by utilizing the RNA interference technology and providing a new experimental means for new strategy of insect control.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for AAT.

The invention relates to epigenetic inheritance modification, and in particular relates to an aspergillus niger NY-1 as well as an improvement technique for improving the insecticidal activity of the aspergillus niger NY-1 and application of the aspergillus niger NY-1. The aspergillus niger NY-1 was collected in China Center for Type Culture Collection (CCTCC) on April 28th, 2014 with the collection number CCTCC NO: M2014169. The chemical epigenetic inheritance modification technique is used for improving the insecticidal activity of an NY-1 fermentation product and is applied to a microbial pesticide. The strain is separated from burdock collected in Anqiu, Shandong; an ITS zone is amplified through PCR, and the sequencing result shows that the similarity of the strain is 100% compared with a strain Aspergillus niger (Accession number: KF358715.1) in a Genebank database. An insecticidal silent gene of the aspergillus niger NY-1 is activated by adopting a chemical epigenetic modifier, so that the insecticidal activity of the NY-1 is improved, and the NY-1 is applied to the microbial pesticide. Compared with gene control and other silent gene activation technologies, the method has the advantages of quickness, low cost, obvious effect and the like.

The invention discloses a mutation screening method of a streptomyces strain SPC6-50-1. The mutation screening method comprises the steps of inducing mutation of streptomyces coelicolor and streptomyces Lzsg6 through nitrosoguanidine to obtain a streptomyces mutant library, and screening the mutant library through rifampicin and streptomycin to obtain a strain with a transcription system and a translation system in mutation. The invention also discloses a streptomyces strain SPC6-50-1 and application thereof. The streptomyces strain SPC6-50-1 disclosed by the invention has the beneficial effects that the strain contains substances having bacteriostatic activities, and the method of nitrosoguanidine (NTG) inducing as well as rifampicin and streptomycin screening can activate silent genes of the streptomyces to obtain a new metabolite, thus obtaining a new antibiotic; meanwhile, the mutation screening method has the advantages of simple operation, short cycle and high efficiency, and is not only applicable to streptomyces but also suitable for such microorganisms as myxobacteria rich in secondary metabolites; the mutation screening method has good popularization and application values.

The invention relates to a cereal cyst nematode Ha34609 protein, an encoding gene and application of the encoding gene. The amino acid sequence of the cereal cyst nematode Ha34609 protein is shown as SEQ ID NO: 1. The nucleotide sequence of the encoding gene is shown as SEQ ID NO: 2. After a silent Ha34609 gene is treated by adopting dsRNA (double-stranded ribonucleic acid), compared with eGFP (enhanced green fluorescent protein) dsRNA, the length and the width of a white female worm are remarkably reduced (t-test, confidence interval: 95%), which indicates that the gene plays an important role in parasitic and pathogenic processes of cereal cyst nematodes and can serve as a target gene of plant nematode resistance engineering. The cereal cyst nematode Ha34609 protein, the encoding gene and the application of the encoding gene have significant values in a study on a nosogenesis of the cyst nematodes and preparation of nematode resistance plants.

The invention provides a siRNA (small interfering Ribonucleic Acid)/anti-cancer drug combined transferring composite supporter and a preparation method and application thereof. The composite supporter comprises a drug liposome and a compressed siRNA in a mass ratio of 20: 1 to 0.5: 1, wherein the drug liposome consists of cationic lipid and a fat soluble medicine in a mass ratio of 200: 1 to 1: 1. According to the preparation method, carbamic acid type cationic lipid is used as a main material for preparing the liposome, the method of compressing a silent gene (siRNA) by a cationic high polymer is used for effectively encapsulating the gene, the targeting and long-circulating modification is performed, and thus a nanoscale novel composite supporter jointly loaded with the anti-cancer drug and the silent gene (siRNA) can be obtained. The preparation method of the composite supporter is simple and efficient; the prepared composite supporter is low in toxicity and high in transfection efficiency; high evaluation effect is obtained from physical characterization and in-vitro biological study.

The invention discloses a biosynthetic gene cluster of cyclic lipopeptide compounds, a method for activating the biosynthetic gene cluster and application thereof. Nucleotide sequences of the biosynthetic gene cluster of the cyclic lipopeptide compounds Totopotensamides are shown as 2972nd-101763rd bit nucleotide sequences in SEQ ID NO.1. The biosynthetic gene cluster, the method and the application have the advantages that all gene and protein information related to the biosynthetic gene cluster of the cyclic lipopeptide compounds Totopotensamides can assist people to understand biosynthesismechanisms of the cyclic lipopeptide compounds Totopotensamides, and materials and knowledge can be increased for further genetic modification; bases can be provided for activating expression of silent gene clusters by means of controlling regulatory genes, natural product biosynthetic gene cluster banks can be enriched, and entity can be provided for discovering lead compounds of medicines.

The invention relates to gene silencing as observed after integration of transgenes into plant genomes. Comparison of transcriptional gene expression between an Arabidopsis line carrying a silent transgene present in multiple copies and its mutant derivative mom1 impaired in silencing of the transgene revealed two cDNA clones which are expressed in the mutant plants, but not in the parental and not in wild type plants. Both clones are derived from the same family of transcripts referred to as TSI (Transcriptionally Silent Information). Genomic templates encoding TSI are repetitive elements with mainly pericentromeric location and conserved organization among various ecotypes. Transcriptional silencing of the genomic TSI templates is specifically released in the mutant. Transcription of TSI can be used as a marker to identify a defective silencing pathway in a plant.